| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Fol-PEG-alpa-CDE (G4) which newly adorned pegylated folate as a cancer cell-selective moiety in alpa-cyclodextrin/dendrimer conjugate (alpa-CDE (G4)) which was the new siRNA carrier developed by us is likely to be useful for as the novel cancer specific and systemic siRNA carrier which has potent stability and blood retention, compared to alpa-CDE (G4) and Fol-PEG-alpa-CDE (G3). We are going to build the novel cancer treatment system which has more potent efficacy and safety in clinical use by constructing the cancer environment-responsible siRNA releasing system appended various functional groups and a co-delivery system of the nucleic acid drug with an anticancer drug, based on Fol-PEG-alpa-CDE (G4).
|
